Nanoparticles and the Immune System

Safety and Effects


Diana Boraschi Albert Duschl



Nanoparticles and the Immune System

Safety and Effects

Diana Boraschi and Albert Duschl







Academic Press is an imprint of Elsevier The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK 225 Wyman Street, Waltham, MA 02451, USA

First published 2014

Copyright © 2014 Elsevier Inc. All rights reserved

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangement with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN: 978-0-12-408085-0

For information on all Academic Press publications visit our website at **store.elsevier.com**

This book has been manufactured using Print On Demand technology. Each copy is produced to order and is limited to black ink. The online version of this book will show color figures where appropriate.



Nanoparticles and the Immune System

PREFACE

This book has the objective to provide a reference text for toxicologists, materials scientists, and regulators by covering the key issues that define interaction of nanomaterials with the immune system. Altering immune responses can lead to many kinds of pathologies; therefore, it is important to make adequate assessments before new nanomaterials are introduced in the market. On the other hand, negative perception and excessive concerns, based on incomplete or misleading results, need to be avoided by communicating existing knowledge and by defining in the future clear endpoints and thresholds for immunosafety regulations.

Nanotoxicology investigations often focus on toxicity leading to death of cells or organisms, while important immune parameters can be affected much earlier and at much lower doses. Some aspects of immunity, for example allergic sensitivity and heightened danger for risk persons with a frail immune system, are usually not covered at all. This gap in nanosafety assessment needs to be filled, not only from a scientific point of view but also for a better implementation of relevant safety regulations. A friend and nanotoxicologist, Jan Mats, told us once: "if we do not consider immunity, we keep studying the mouse without seeing the elephant in the room." To increase the awareness of the importance of immunity in nanotoxicology, several years ago we started the Immunosafety Focus Group within the Working Group "Hazard" of the EU-supported NanoSafety Cluster, and this book intends to disseminate knowledge gained by the research community in this field.

The book covers several issues that all stakeholders in nanotechnology should be aware of: identification of endpoints that are relevant for assessing hazard, evaluating impact on immunologically frail populations, considering allergic responses, and how to evaluate chronic/cumulative effects. In addition, the book addresses a very important issue, that is, how to shape and turn the immunomodulating properties of nanomaterials to our advantage for preventive strategies (such as vaccination) or for therapeutic approaches in diseases where immunostimulation is

desired (infections, tumors) or where immunosuppression in needed (inflammatory diseases, allergies, autoimmunity).

Our goal is to raise awareness about the effects of nanomaterials on our immune system, in order to ensure a safe design or safe use of such materials. We also want to emphasize an especially useful role of the immune system: it has been optimized by evolution to identify whether or not specific foreign materials are dangerous to the body. Finding that out is also the key question in nanosafety, so knowing the opinion of the professional immune cells should be of particular interest to us.

Diana Boraschi and Albert Duschl

ACKNOWLEDGMENTS

The editors Diana Boraschi and Albert Duschl wish to thank the many individuals who have stimulated them in various occasions (publications, presentations at congresses, personal discussions) to put the immune response toward nanomaterials into the general context of immunity. We thank our working groups for giving us input on many questions and for being patient when we were unavailable due to intense work on the book. Most of all, we thank our partners, Aldo and Jutta, who have supported us with their patience and attention, and who granted us the time to work on this book.

The research leading to this book has received support from the European Union Seventh Framework Programme (FP7/2007–2013) projects NanoEIS (NMP-2012-CSA-6-GA 319054; AD), NanoValid (NMP-2010-1.3-1-GA 263147; AD), NanoTOES (PITN-GA-2010-2645506; AD and DB), NANOREG (NMP-LA-2013-310584; DB), HUMUNITY (PITN-GA-2012-316383; DB), and QualityNano (INFRA-2010-262163; DB).

Albert Duschl gratefully acknowledges support from the research cluster "Biosciences and Health" of the University of Salzburg.

Diana Boraschi gratefully acknowledges the support from the Fondazione Cariplo within the project "Inter-cellular delivery, trafficking and toxicity of engineered magnetic nanoparticles in macrophages and CNS cells."

S. Moein Moghimi gratefully acknowledges the support by the Danish Agency for Science, Technology and Innovation (Det Strategiske Forskningsråd), reference 09-065746.

Laura Canesi wishes to thank Caterina Ciacci (University of Urbino, Italy) and Rita Fabbri (University of Genoa, Italy) for their invaluable technical assistance in the experimental work on nanoparticles and mussel immunocytes, and Gabriella Gallo for her foresight, support, and encouragement in exploring new fields of research.

Petra Procházková wishes to thank Martin Bilej and Radka Roubalová for critical reading of the manuscript, and gratefully acknowledges support by the Ministry of Education, Youth and Sports (CZ.1.07/2.3.00/20.0055), and the Institutional Research Concepts RVO 61388971 and RVO 60077344.

CONTRIBUTORS

Diana Boraschi

CNR, Institute of Protein Biochemistry, Napoli, Italy

Laura Canesi

DISTAV, Department of Earth, Environmental and Life Sciences, University of Genoa, Genoa, Italy

Albert Duschl

Department of Molecular Biology, University of Salzburg, Salzburg, Austria

Z. Shadi Farhangrazi

Biotrends International, Denver Technology Center, Greenwood Village, CO, USA

S. Moein Moghimi

Nanomedicine Research Group, Centre for Pharmaceutical Nanotechnology and Nanotoxicology, University of Copenhagen; Denmark and NanoScience Centre, University of Copenhagen, Copenhagen, Denmark

Petra Procházková

Institute of Microbiology of the Academy of Sciences of the Czech Republic, Prague 4, Czech Republic

CONTENTS

Preface	IX
Acknowledgments	xi
Contributors	xiii
Chapter 1 How Innate and Adaptive Immunity Work	1
Diana Boraschi	
1.1 The Immune System: Protecting the Body from Damage	1
1.2 Innate Immunity	2
1.3 Adaptive Immunity	5
1.4 Nanoparticles and the Immune System	6
Reference	7
Chapter 2 Nanoparticles and Innate Immunity	9
Diana Boraschi	
2.1 The Innate Immune System	9
2.2 The Innate Immune Cells	10
2.3 Sensing of Nanoparticles by Innate Immune Cells	11
2.4 Interaction of Nanoparticles with Innate Immune Cells	17
2.5 Interaction with Innate Immune Factors	19
2.6 Innate Immune Reaction to Nanoparticles: Healing Versus	
Chronic Inflammation	26
References	29
Chapter 3 Nanoparticles and Adaptive Immunity	33
Albert Duschl	
3.1 Adaptive Immunity—Differences and Cooperation	
with Innate Immunity	33
3.2 De Novo Induction of Adaptive Immunity: MHC Complexes	
and Dendritic Cells	37
3.3 T Cell Subtypes	39

3.4	Regulating Adaptive Immunity: Regulatory T Cells and Anergy Versus Inflammatory T Cells	
3.5	B Cells and Antibodies	
	Toxicity at the Level of Specific Immune Cell Types: Does it Exist?	
Ref	erences	
Cha	Albert Duschl	55
4.1	Allergy: A Special Case of Immune Reaction	55
4.2	Nanoparticles in the Sensitization Phase of Allergy	58
4.3	Nanoparticles and the Response Against Allergens	61
4.4	Sensitizers, Contact Allergy, Delayed-Type Allergy	63
4.5	Therapeutic Perspectives	65
Ref	erences	65
Cha	apter 5 Nanoparticles and Immunological Frailty	69
	Diana Boraschi	
	When Does Immunological Frailty Occur?	
5.2	Disease	71
5.3	Aging	72
5.4	Interaction of Nanoparticles with Frail Immune Systems	73
Ref	erences	74
Cha	apter 6 Nanoparticles in Medicine: Nanoparticle Engineering for Macrophage Targeting and Nanoparticles	
	that Avoid Macrophage Recognition	11
<i>c</i> 1	S. Moein Moghimi and Z. Shadi Farhangrazi	77
	Introduction	
	Macrophage Distribution, Activation, and Heterogeneity	
	Macrophage Recognition of Nanoparticles	
	Macrophage Avoidance of Nanoparticles	
	Other Challenges	86

Chapter	7 The Invertebrate Immune System as a Model
	for Investigating the Environmental
	Impact of Nanoparticles91
	Laura Canesi and Petra Procházková
7.1 Brie	ef Overview of Invertebrate Immunity91
	ertebrate Immunity as a Target for Environmental noparticles
Inv	alve Molluscs as an Invertebrate Model for estigating the Effects of Nanoparticles on Innate Immunity Aquatic Environments98
of I	thworms as a Model for Investigating the Effects Nanoparticles on Innate Immunity on Terrestrial ertebrates
7.5 Co	nclusions107
Referen	ces108
Chapter	8 Summary and Outlook
8.1 The	e Role of Immunity in Nanosafety113
8.2 Cha	allenges for the Further Development of the Field115
8.3 Un	derstanding Molecular Mechanisms117
8.4 Ap	plying Nanotechnology in Immunology119
Referen	ces120
Glossar	y123



How Innate and Adaptive Immunity Work

Diana Boraschi

CNR, Institute of Protein Biochemistry, Napoli, Italy

1.1 THE IMMUNE SYSTEM: PROTECTING THE BODY FROM DAMAGE

The human body exists in a hostile environment. Besides macroscopic dangers, the body needs to defend its integrity from the invisible attacks by infectious agents (bacteria, viruses, unicellular and multicellular parasites), poisons, and contaminants in air, water, and food. Other dangers come from within, those posed by the senescence, damage, or anomalous behavior of the body's own cells and tissues.

The survival and integrity of our body relies on a very sophisticated system of recognition of danger and of reaction to it, the immune system [1]. The immune system is a complex of cells and soluble factors, scattered throughout the entire body, which has the function of surveilling the body's well-being, by detecting and eliminating potentially dangerous events/agents. The immune cells patrol the body, and in particular the areas more exposed to the external environment (skin, mucosal surfaces of lung, gut, and reproductive organs). Molecules or agents that pass the mechanical barriers (mucus, keratinized epithelium, mucosa) are sampled by immune cells, which decide whether the foreign element may represent a danger or not, and act consequently. If the nonself element is considered to be a threat, the immune system mounts a defensive reaction to destroy the agents that are considered as potentially dangerous.

Which are the optimal characteristics of an effective immune response? Two are particularly important:

 Rapidity: The immune reaction must be fast, leaving no time to the dangerous agent to multiply and gain access to the inner body and cause serious damage. 2. Specificity: The immune system must be able to discriminate between what is dangerous and what is not, so as to target the dangerous agent only and spare the surrounding cells and tissues.

How can the immune system reach the opposing goals of being both rapid and specific? In fact, being quick means having no time for developing sophisticated specific weapons, it is like firing cannonballs, which may well destroy the target but also cause substantial collateral damage. On the other hand, being specific means that some time is required for designing and building the right tools, but the risk is that during this time the dangerous agent may further invade the organism and endanger its survival.

This is why, in higher vertebrates including man, two immune systems are active in parallel. The innate immune system is the more primitive, rapid, and nonspecific system, with prebuilt weapons always ready to be fired. The adaptive immune system on the other hand is the sophisticated and highly specific system that, each time a dangerous agent comes in, builds new weapons specifically targeting that agent. The adaptive immune system has an additional characteristic, it can learn. This means that after having encountered a foreign agent and having designed and built the specific weapons, the cells of the system keep memory of what they have done and, if the same agent is encountered again (for instance an infective virus), the system can rebuild the specific weapons much faster and get rid of the infection much quicker.

The innate immune system is the defensive system that is already present in plants and lower animals (insects, worms, sponges, etc.). Adaptive immunity developed as consequence of a single molecular event in bony fish and, due to its evolutionary advantage for larger and long-lived species, it has been maintained and expanded into highly sophisticated system in higher vertebrates. Thus, man possesses both immune systems acting in concert. Table 1.1 summarizes the main characteristics of innate and adaptive immunity.

1.2 INNATE IMMUNITY

The innate immune system (see Chapter 2 for full details) is the more primitive defense system and is based primarily on phagocytosis [1]. Foreign agents and particles, as well as damaged cells of the own